The Cystic Fibrosis Foundation in Maryland has invested an additional $14 million into Framingham firm Synspira Therapeutics, a biopharmaceutical company, as it pursues clinical studies.
The new funding brings the foundation’s total commitment to $22.55 million. The funds will allow Synspira to complete preclinical and initial clinical development of an enzyme replacement therapy and advance a treatment for pulmonary infections and complications through late stage clinical studies, according to a release from the company.
The two treatments being developed are designed to address issues confronting patients with cystic fibrosis.Â
The Miller Family Trust, a founding investor in Synspira, will continue to invest along with the Cystic Fibrosis Foundation, according to the newsletter.
